Orphan status of Vpriv blocks Pfizer/Protalix's Elelyso at CHMP
This article was originally published in Scrip
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that Pfizer/Protalix Biotherapeutics' type 1 Gaucher disease treatment Elelyso (taliglucerase alfa) be refused marketing authorisation. The problem is that Shire's Vpriv (velaglucerase alfa), which was authorised for Gaucher disease in August 2010, had been granted 10-year market exclusivity as an orphan drug, effectively blocking Elelyso from the European market.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.